Myriad Genetics
MYGN | NASDAQ
$5.57
-$0.09 (-1.59%)
At close: Nov 16, 2026, 4:00 PM ET
$5.57
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 5:56 PM ET
-1.59%
(1D)No price chart data available for 1D timeframe.
Rating
26.2
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #893/1021 (Top 87%)
Key Statistics
Market Data
Market Cap $534.29M
1D Range
5.48 5.65
52W Range
2.86 7.91
Valuation (TTM)
PE -4.10
PB 1.99
EV/EBITDA -8.50
Valuation (NTM)
Forward PE 36.09
Forward PEG 0.00
Price Target $5.00
Cash Flow
FCF Yield -6.3%
SBC Adj. FCF Yield -9.3%
SBC Impact -49.4%
Margins
Gross Margin 68.3%
Operating Margin -14.3%
FCF Margin -4.2%
Growth (CAGR)
Revenue 3Y | 5Y 3.0% |
8.7%
Dil EPS 3Y | 5Y -1.3% |
-7.7%
FCF 3Y | 5Y 64.3% |
38.1%
Returns
ROA -21.2%
ROE -40.4%
ROIC -24.0%
Financial Health
Net Debt
$14M
Current Ratio 1.98
Interest Coverage -6.90
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomic...
Sector Healthcare
Industry Medical - Diagnostics & Research
Employees 2,700
IPO Date Oct 6, 1995
Website www.myriad.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 4, 2026
EPS
-$0.11
Beat +44.88%
YoY:
+15.38% REV
$202.7M
Beat +5.94%
YoY:
-1.46%Next Earnings
Feb 22, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
7
Consensus
Hold
Price Target
$5.00
Downside
-10.23%
Buy (1)
Hold (5)
Sell (1)
Add to Watchlist
Select watchlists to add or remove MYGN